These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21715311)

  • 1. Targeting survivin overcomes drug resistance in acute lymphoblastic leukemia.
    Park E; Gang EJ; Hsieh YT; Schaefer P; Chae S; Klemm L; Huantes S; Loh M; Conway EM; Kang ES; Hoe Koo H; Hofmann WK; Heisterkamp N; Pelus L; Keerthivasan G; Crispino J; Kahn M; Müschen M; Kim YM
    Blood; 2011 Aug; 118(8):2191-9. PubMed ID: 21715311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endogenous knockdown of survivin improves chemotherapeutic response in ALL models.
    Morrison DJ; Hogan LE; Condos G; Bhatla T; Germino N; Moskowitz NP; Lee L; Bhojwani D; Horton TM; Belitskaya-Levy I; Greenberger LM; Horak ID; Grupp SA; Teachey DT; Raetz EA; Carroll WL
    Leukemia; 2012 Feb; 26(2):271-9. PubMed ID: 21844871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia.
    Gang EJ; Hsieh YT; Pham J; Zhao Y; Nguyen C; Huantes S; Park E; Naing K; Klemm L; Swaminathan S; Conway EM; Pelus LM; Crispino J; Mullighan CG; McMillan M; Müschen M; Kahn M; Kim YM
    Oncogene; 2014 Apr; 33(17):2169-78. PubMed ID: 23728349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of EZN-3042, a novel survivin messenger ribonucleic acid (mRNA) antagonist, administered in combination with chemotherapy in children with relapsed acute lymphoblastic leukemia (ALL): a report from the therapeutic advances in childhood leukemia and lymphoma (TACL) consortium.
    Raetz EA; Morrison D; Romanos-Sirakis E; Gaynon P; Sposto R; Bhojwani D; Bostrom BC; Brown P; Eckroth E; Cassar J; Malvar J; Buchbinder A; Carroll WL
    J Pediatr Hematol Oncol; 2014 Aug; 36(6):458-63. PubMed ID: 24276047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin as a therapeutic target in Sonic hedgehog-driven medulloblastoma.
    Brun SN; Markant SL; Esparza LA; Garcia G; Terry D; Huang JM; Pavlyukov MS; Li XN; Grant GA; Crawford JR; Levy ML; Conway EM; Smith LH; Nakano I; Berezov A; Greene MI; Wang Q; Wechsler-Reya RJ
    Oncogene; 2015 Jul; 34(29):3770-9. PubMed ID: 25241898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
    Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
    Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting survivin and p53 in pediatric acute lymphoblastic leukemia.
    Tyner JW; Jemal AM; Thayer M; Druker BJ; Chang BH
    Leukemia; 2012 Apr; 26(4):623-32. PubMed ID: 21960246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. siRNA-mediated silencing of survivin inhibits proliferation and enhances etoposide chemosensitivity in acute myeloid leukemia cells.
    Karami H; Baradaran B; Esfahani A; Estiar MA; Naghavi-Behzad M; Sakhinia M; Sakhinia E
    Asian Pac J Cancer Prev; 2013; 14(12):7719-24. PubMed ID: 24460358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide.
    Sapra P; Wang M; Bandaru R; Zhao H; Greenberger LM; Horak ID
    Nucleosides Nucleotides Nucleic Acids; 2010 Feb; 29(2):97-112. PubMed ID: 20391197
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin.
    Tian H; Liu S; Zhang J; Zhang S; Cheng L; Li C; Zhang X; Dail L; Fan P; Dai L; Yan N; Wang R; Wei Y; Deng H
    J Biomed Nanotechnol; 2012 Aug; 8(4):633-41. PubMed ID: 22852473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.
    Luk SU; Xue H; Cheng H; Lin D; Gout PW; Fazli L; Collins CC; Gleave ME; Wang Y
    Oncotarget; 2014 Aug; 5(16):6896-908. PubMed ID: 25071009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of survivin siRNA with neoadjuvant chemotherapy enhances apoptosis and reverses drug resistance in breast cancer MCF-7 cells.
    Dong H; Yao L; Bi W; Wang F; Song W; Lv Y
    J Cancer Res Ther; 2015; 11(4):717-22. PubMed ID: 26881507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapamycin enhances docetaxel-induced cytotoxicity in a androgen-independent prostate cancer xenograft model by survivin downregulation.
    Morikawa Y; Koike H; Sekine Y; Matsui H; Shibata Y; Ito K; Suzuki K
    Biochem Biophys Res Commun; 2012 Mar; 419(3):584-9. PubMed ID: 22387542
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase-I trial of survivin inhibition with EZN-3042 in dogs with spontaneous lymphoma.
    Thamm DH; Joseph JK; Rose BJ; Meuten TK; Weishaar KM
    BMC Vet Res; 2020 Mar; 16(1):97. PubMed ID: 32209084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia.
    Shi PJ; Xu LH; Lin KY; Weng WJ; Fang JP
    J Hematol Oncol; 2016 Feb; 9():12. PubMed ID: 26892465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
    Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
    Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KLF5 Interacts with p53 in regulating survivin expression in acute lymphoblastic leukemia.
    Zhu N; Gu L; Findley HW; Chen C; Dong JT; Yang L; Zhou M
    J Biol Chem; 2006 May; 281(21):14711-8. PubMed ID: 16595680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidating minimal residual disease of paediatric B-cell acute lymphoblastic leukaemia by single-cell analysis.
    Zhang Y; Wang S; Zhang J; Liu C; Li X; Guo W; Duan Y; Chen X; Zong S; Zheng J; Wu Y; Chen X; Cheng X; Chang Y; Wang Y; Ding F; Yang W; Chen X; Guo Y; Zhang L; Chen Y; Zou Y; Zhu X; Gu J; Cheng T
    Nat Cell Biol; 2022 Feb; 24(2):242-252. PubMed ID: 35145224
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lentiviral vector-mediated survivin shRNA delivery in gastric cancer cell lines significantly inhibits cell proliferation and tumor growth.
    Habib R; Akhtar J; Taqi M; Yu C; Zhang C
    Oncol Rep; 2015 Aug; 34(2):859-67. PubMed ID: 26043753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.